Status:
COMPLETED
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Aarhus University Hospital Skejby
Aarhus University Hospital
Conditions:
Acromegaly
Insulin Resistance
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensi...
Eligibility Criteria
Inclusion
- Age \> 18
- Diagnosed with acromegaly
- Safe anticonceptive for fertile women
- Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH \< 0.5 µg/l.)
Exclusion
- Pregnancy
- Liver disease
- Diabetes mellitus type I
- Magnetic or electronic implants
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00652379
Start Date
June 1 2008
End Date
May 1 2011
Last Update
January 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Aarhus University Hospital
Aarhus C, Aarhus, Denmark, 8000